VBIV - מחיר רכישת החברה VBI Vaccines

VBI Vaccines Inc. (VBIV) faces challenges in developing antiviral agents due to geopolitical tensions that are obstructing component logistics and the execution of tests. To compete with market leaders, VBI Vaccines Inc. (VBIV) employs flexible pricing for its vaccines by offering discounts to insurers. The asset's price trajectory, where the Enterprise Value stands at , confirms the business's resilience to crises driven by stable demand for preventive medicine.

Enterprise Value represents the total buyout price of a business, combining market capitalization and net debt. By analyzing fluctuations in enterprise value, an investor assesses the real financial burden of VBI Vaccines Inc. (VBIV), including capital-intensive expenditures for ESG compliance regarding safe waste disposal and the implementation of energy-saving technologies in biotechnological production.